APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.
Hepatol Int
; 15(5): 1031-1048, 2021 Oct.
Article
en En
| MEDLINE
| ID: mdl-34427860
ABSTRACT
BACKGROUND & AIM:
Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation.METHODS:
All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation.RECOMMENDATIONS:
We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Hepatitis B Crónica
/
Hepatitis B
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Hepatol Int
Año:
2021
Tipo del documento:
Article
País de afiliación:
China